Some of the most ambitious cancer science is happening in a disease few outside of oncology can name, and it’s revealing a future where cancer is no longer a death sentence.

Multiple myeloma (MM) is a blood cancer that affects the body’s plasma cells, causing them to mutate and grow uncontrollably in the bone marrow. These plasma cells produce abnormal antibodies called “M-proteins” that wreak havoc on the immune system, kidneys, and bones.

MM is also relatively rare. While breast cancer saw approximately 370,000 new cases in the U.S. in 2024, multiple myeloma only saw about 31,600, per internal data from Evaluate. Even among blood cancers, MM only makes up 10% of cases.

Yet, despite its rarity, multiple myeloma has become a springboard for some of the most advanced drug innovations in

See Full Page